These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25048312)

  • 1. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Gombert-Handoko KB
    Clin Ther; 2014 Nov; 36(11):1704. PubMed ID: 25048312
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial design for breakthrough pain: is it ethical to have a placebo in a trial?
    Davis MP; Bruera E
    Clin Ther; 2014 May; 36(5):814-5. PubMed ID: 24726089
    [No Abstract]   [Full Text] [Related]  

  • 4. Trial design for breakthrough pain: is it ethical to have a placebo in a trial? Author reply.
    Trinquet F
    Clin Ther; 2014 May; 36(5):816. PubMed ID: 24726087
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial.
    Shimoyama N; Gomyo I; Katakami N; Okada M; Yukitoshi N; Ohta E; Shimoyama M
    Int J Clin Oncol; 2015 Feb; 20(1):198-206. PubMed ID: 24839047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of oral formulations of fentanyl for breakthrough cancer pain.
    Handsaker S; Dempsey L; Fabby C
    Int J Palliat Nurs; 2015 Apr; 21(4):168, 170-2. PubMed ID: 25901588
    [No Abstract]   [Full Text] [Related]  

  • 7. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
    Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
    [No Abstract]   [Full Text] [Related]  

  • 8. Fentanyl citrate sublingual formulation (Vellofent®) for quick BTcP hindering.
    Romualdi P; Candeletti S
    Minerva Med; 2016 Apr; 107(2):114-22. PubMed ID: 27064584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there cost benefits to fentanyl for breakthrough pain?
    Davis MP
    J Pain Symptom Manage; 2012 Sep; 44(3):e1-2. PubMed ID: 22939453
    [No Abstract]   [Full Text] [Related]  

  • 10. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
    Alberts DS; Smith CC; Parikh N; Rauck RL
    Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
    Núñez-Olarte JM; Alvarez-Jiménez P
    J Pain Symptom Manage; 2011 Dec; 42(6):e6-8. PubMed ID: 22048003
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence-based treatment of cancer-related breakthrough pain with opioids.
    Zeppetella G
    J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
    Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
    Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction with intranasal fentanyl for breakthrough pain.
    Veldhorst-Janssen NM; Fiddelers AA; Zandstra H; Kessels AG; Zandstra H; Marcus MA; Neef C; van der Kuy PH
    J Palliat Med; 2012 Jun; 15(6):631-2. PubMed ID: 22656053
    [No Abstract]   [Full Text] [Related]  

  • 16. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
    Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD004311. PubMed ID: 26275024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fentanyl: fast and furious?].
    Meissner W; Sabatowski R
    Anaesthesist; 2013 Jun; 62(6):429-30. PubMed ID: 23748418
    [No Abstract]   [Full Text] [Related]  

  • 19. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.
    Mercadante S; Adile C; Cuomo A; Aielli F; Marinangeli F; Casuccio A
    Support Care Cancer; 2017 Feb; 25(2):645-649. PubMed ID: 27744534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.